The Mission of the Yale Center for Molecular Discovery (YCMD) is to blend innovative research capabilities and practical experience to develop a nimble means to accelerate basic scientific concepts into innovative applications. YCMD works with investigators with breakthrough ideas and works with them to accelerate and broaden the potential for new grants, manuscripts and future partnerships. Our mission is accomplished using a mix of internal laboratory expertise with consultative services to provide customized solutions for the unique challenges of each project. YCMD seeks to synergize existing technologies and expertise in a manner that expands the quality and breadth of services to investigators in a cost-effective manner. Prominent services include the development of robust assays for high content and/or high-throughput screening. Complementing this, YCMD amassed the reagents and expertise to conduct screening campaigns with small molecule and/or siRNA libraries. These activities have been successfully utilized to facilitate the discovery and prosecution of new targets that are relevant to cancer. Recently, YCMDs impact increased by providing much-needed chemistry-based services, including ligand and structure based design, compound synthesis and analoging and natural product library generation. Beyond the discovery of novel targets and agents, YCMD works with Yale Cancer Center investigators to identify opportunities for synergistic combination of known antitumor agents. Each project is tailored to meet the specific needs of our customers. Key considerations for each project are the time, cost, and probability of meeting the investigator research goal. In partnership with a representative from each laboratory, we combine precise knowledge of the research field and specific handling considerations of experimental reagents. Barriers to new technology can be daunting, especially those involving sophisticated instrumentation;thus we streamline and direct the screening process for each project to maximize efficiency of all resources.
The Yale Center for Molecular Discovery (YCMD) works with investigators with breakthrough ideas and works with them to accelerate and broaden the potential for new grants, manuscripts and future partnerships. YCMD's mission is accomplished using a mix of internal laboratory expertise with consultative services to provide customized solutions for the unique challenges of each project.
|Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309|
|Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196|
|Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845|
|Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011|
|Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326|
|Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083|
|Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291|
|Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40|
|Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631|
|Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025|
Showing the most recent 10 out of 675 publications